Skip to main content
. 2017 Feb 10;31(10):2151–2160. doi: 10.1038/leu.2017.8

Figure 5.

Figure 5

CD5CAR NK-92 cells exhibit dose-dependent target cell lysis. (a) CD5CAR NK-92 cells show dose-dependent lysis of normal primary patient T-cells as the ratio is increased from a lowered E:T ratio of 0.25:1 to standard E:T ratios of 5:1 and reaching saturation. (b) CD5CAR NK-92 cells lyse malignant CD5+ PT4 patient cells in a dose-dependent manner as the E:T ratio is increased, reaching lysis saturation at 5:1. (c) CD5CAR NK-92 cells lyse T-ALL 2 CD5+ patient sample cells in a dose-dependent manner as the E:T ratio is increased, reaching saturation at 5:1 with significant activity observed for dosages as low as 0.25:1. (d) The CD5CAR NK-92 summary panel of CAR activity in lysing T-ALL cell lines and primary human samples. All T-ALL and primary samples expressing CD5 demonstrate targeting and lysis by CD5CAR NK-92 cells, with 8/10 CD5+ samples showing a percentage lysis of >80% for both E:T ratios. Percent lysis values were determined using the total CD5+ populations after gating for viability against the vector control NK-92 treatment.